Novo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of “Hold” from Analysts

Novo Nordisk A/S (NYSE:NVO) has received a consensus recommendation of “Hold” from the thirteen brokerages that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $135.00.

A number of research analysts have recently issued reports on NVO shares. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating on the stock. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th.

Institutional Investors Weigh In On Novo Nordisk A/S

Large investors have recently made changes to their positions in the stock. Center for Financial Planning Inc. lifted its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL increased its holdings in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $27,000. Finally, Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 2.9%

Shares of NYSE:NVO opened at $67.70 on Tuesday. The business’s 50 day moving average is $68.75 and its 200 day moving average is $85.51. The stock has a market cap of $303.79 billion, a P/E ratio of 20.58, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.